Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Erectile Dysfunction-Pipeline Review, H1 2015

Erectile Dysfunction-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Erectile Dysfunction-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Erectile Dysfunction-Pipeline Review, H1 2015', provides an overview of the Erectile Dysfunction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Erectile Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Erectile Dysfunction

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Erectile Dysfunction and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Erectile Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Erectile Dysfunction

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Erectile Dysfunction pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Erectile Dysfunction Overview 9

Therapeutics Development 10

Pipeline Products for Erectile Dysfunction-Overview 10

Pipeline Products for Erectile Dysfunction-Comparative Analysis 11

Erectile Dysfunction-Therapeutics under Development by Companies 12

Erectile Dysfunction-Therapeutics under Investigation by Universities/Institutes 14

Erectile Dysfunction-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Erectile Dysfunction-Products under Development by Companies 19

Erectile Dysfunction-Products under Investigation by Universities/Institutes 21

Erectile Dysfunction-Companies Involved in Therapeutics Development 22

Acorda Therapeutics, Inc. 22

Apricus Biosciences, Inc. 23

Aprogen, Inc. 24

Bioheart, Inc. 25

Biolab Sanus Farmaceutica Ltda. 26

Corridor Pharmaceuticals Inc. 27

Furiex Pharmaceuticals, Inc. 28

Futura Medical plc 29

Hanmi Pharmaceuticals, Co. Ltd. 30

IntelGenx Corp. 31

Mezzion Pharma Co. Ltd. 32

Mitsubishi Tanabe Pharma Corporation 33

NAL Pharmaceuticals Ltd. 34

Pacific Therapeutics Ltd. 35

Palatin Technologies, Inc. 36

Pharmicell Co., Ltd. 37

Sagene Pharmaceuticals, Inc. 38

Suda Ltd 39

Yungjin Pharm Ind. Co., Ltd. 40

Erectile Dysfunction-Therapeutics Assessment 41

Assessment by Monotherapy Products 41

Assessment by Combination Products 42

Assessment by Target 43

Assessment by Mechanism of Action 45

Assessment by Route of Administration 47

Assessment by Molecule Type 49

Drug Profiles 51

AdipoCell-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

alprostadil-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

AP-102-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

BL-214-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

cimaglermin alfa-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

dapoxetine hydrochloride-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

HCP-1302-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

HCP-1303-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Immpocellgram-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

MED-2002-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Next Generation Melanocortin Receptor IV Agonist-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

PL-6983-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

selegiline + PDE-5 Inhibitor-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

sildenafil citrate-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

sildenafil citrate-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

sildenafil citrate-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

T-6932-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

tadalafil-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

tadalafil-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

TPN-729-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

udenafil-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

YBH-1603-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

Erectile Dysfunction-Recent Pipeline Updates 83

Erectile Dysfunction-Dormant Projects 94

Erectile Dysfunction-Discontinued Products 97

Erectile Dysfunction-Product Development Milestones 98

Featured News & Press Releases 98

Feb 24, 2014: IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm Tadalafil Product 98

Aug 28, 2012: Acorda Announces GGF2 Preclinical Data On Treatment Of Erectile Dysfunction 98

Jul 18, 2012: Zydus Urosciences Launches Udenafil For Treatment Of Erectile Dysfunction In India 99

Sep 08, 2011: Sagene Completes Pre-IND Meeting With FDA For Dual-Action Erectile Dysfunction Drug 99

Oct 12, 2010: Dong-A Launches Zydena For Daily Treatment Of Erectile Dysfunction In Korea 100

Sep 02, 2010: IntelGenx Achieves Positive Bioequivalence Results For Erectile Dysfunction Film Product 100

Nov 19, 2009: Once-A-Day Dosing Clinical Study Of Udenafil For Erectile Dysfunction Completed By Dong-A Pharmaceutical Co., Ltd. 100

Nov 11, 2009: ZYDENA Poised To Enter Global Market With Phase III Clinical Trial Starting For US FDA Approval 101

Sep 11, 2009: New Drug Udenafil By Dong-A PharmTech Co. Ltd For Erectile Dysfunction in US Trials 102

Aug 28, 2009: Dong-A Receives Approval For Zydena For Treatment Of Erectile Dysfunction 102

Appendix 103

Methodology 103

Coverage 103

Secondary Research 103

Primary Research 103

Expert Panel Validation 103

Contact Us 104

Disclaimer 104

List of Tables

Number of Products under Development for Erectile Dysfunction, H1 2015 10

Number of Products under Development for Erectile Dysfunction-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Comparative Analysis by Unknown Stage Development, H1 2015 18

Products under Development by Companies, H1 2015 19

Products under Development by Companies, H1 2015 (Contd..1) 20

Products under Investigation by Universities/Institutes, H1 2015 21

Erectile Dysfunction-Pipeline by Acorda Therapeutics, Inc., H1 2015 22

Erectile Dysfunction-Pipeline by Apricus Biosciences, Inc., H1 2015 23

Erectile Dysfunction-Pipeline by Aprogen, Inc., H1 2015 24

Erectile Dysfunction-Pipeline by Bioheart, Inc., H1 2015 25

Erectile Dysfunction-Pipeline by Biolab Sanus Farmaceutica Ltda., H1 2015 26

Erectile Dysfunction-Pipeline by Corridor Pharmaceuticals Inc., H1 2015 27

Erectile Dysfunction-Pipeline by Furiex Pharmaceuticals, Inc., H1 2015 28

Erectile Dysfunction-Pipeline by Futura Medical plc, H1 2015 29

Erectile Dysfunction-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 30

Erectile Dysfunction-Pipeline by IntelGenx Corp., H1 2015 31

Erectile Dysfunction-Pipeline by Mezzion Pharma Co. Ltd., H1 2015 32

Erectile Dysfunction-Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 33

Erectile Dysfunction-Pipeline by NAL Pharmaceuticals Ltd., H1 2015 34

Erectile Dysfunction-Pipeline by Pacific Therapeutics Ltd., H1 2015 35

Erectile Dysfunction-Pipeline by Palatin Technologies, Inc., H1 2015 36

Erectile Dysfunction-Pipeline by Pharmicell Co., Ltd., H1 2015 37

Erectile Dysfunction-Pipeline by Sagene Pharmaceuticals, Inc., H1 2015 38

Erectile Dysfunction-Pipeline by Suda Ltd, H1 2015 39

Erectile Dysfunction-Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2015 40

Assessment by Monotherapy Products, H1 2015 41

Assessment by Combination Products, H1 2015 42

Number of Products by Stage and Target, H1 2015 44

Number of Products by Stage and Mechanism of Action, H1 2015 46

Number of Products by Stage and Route of Administration, H1 2015 48

Number of Products by Stage and Molecule Type, H1 2015 50

Erectile Dysfunction Therapeutics-Recent Pipeline Updates, H1 2015 83

Erectile Dysfunction-Dormant Projects, H1 2015 94

Erectile Dysfunction-Dormant Projects (Contd..1), H1 2015 95

Erectile Dysfunction-Dormant Projects (Contd..2), H1 2015 96

Erectile Dysfunction-Discontinued Products, H1 2015 97

List of Figures

Number of Products under Development for Erectile Dysfunction, H1 2015 10

Number of Products under Development for Erectile Dysfunction-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Products, H1 2015 17

Assessment by Monotherapy Products, H1 2015 41

Number of Products by Top 10 Targets, H1 2015 43

Number of Products by Stage and Top 10 Targets, H1 2015 43

Number of Products by Top 10 Mechanism of Actions, H1 2015 45

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 46

Number of Products by Top 10 Routes of Administration, H1 2015 47

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 48

Number of Products by Top 10 Molecule Types, H1 2015 49

Number of Products by Stage and Top 10 Molecule Types, H1 2015 50

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Acorda Therapeutics, Inc.

Apricus Biosciences, Inc.

Aprogen, Inc.

Bioheart, Inc.

Biolab Sanus Farmaceutica Ltda.

Corridor Pharmaceuticals Inc.

Furiex Pharmaceuticals, Inc.

Futura Medical plc

Hanmi Pharmaceuticals, Co. Ltd.

IntelGenx Corp.

Mezzion Pharma Co. Ltd.

Mitsubishi Tanabe Pharma Corporation

NAL Pharmaceuticals Ltd.

Pacific Therapeutics Ltd.

Palatin Technologies, Inc.

Pharmicell Co., Ltd.

Sagene Pharmaceuticals, Inc.

Suda Ltd

Yungjin Pharm Ind. Co., Ltd.

Erectile Dysfunction Therapeutic Products under Development, Key Players in Erectile Dysfunction Therapeutics, Erectile Dysfunction Pipeline Overview, Erectile Dysfunction Pipeline, Erectile Dysfunction Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com